Corporate Overview
October 2023
NASDAQ: NEXI
This presentation ("Presentation") contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NexImmune, Inc. (the “Company” or “NexImmune”). All statements other than statements of historical fact contained in this presentation are forward-looking statements, including statements concerning the Company’s the enrollment, timing, progress, release of data from and results of the Company’s paused clinical trial and the expectations with respect to potential AIM INJ product candidates; the timing, progress, release of preclinical data from, and regulatory pathway for our AIM INJ platform programs and other preclinical research programs; the potential advantages of the Company’s technology platform; the Company’s goals with respect to the development and potential use, if approved, of each of its product candidates and its technology platform; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission ("SEC") on March 29, 2023, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this presentation. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this presentation to conform any of the forward-looking statements to actual results or to changes in its expectations.

This Presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. This Presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.
AIM™ Platform:

Develop Therapies that Drive Antigen-Specific Cell-Mediated Immune Responses with Curative Potential

Rationally designed synthetic dendritic cell (nanoparticle) based therapeutics

Target-specific killing

“Intensifying” immune response
(Cancer, Infectious Disease)

Target-specific T Cell Tolerance

“Suppressing” or deleting immune response
(Autoimmune Disorders)

Our Company
Directing antigen-specific responses is one of the top priorities in immunology, though the next wave of breakthroughs has been elusive

Drive multi-antigen T cell mediated durable response

**Blood cancers**

- Greatest progress and approvals in blood cancers
- Novel approaches (e.g. CAR-T, bispecific TCE*) are limited to a few well-characterized surface targets (e.g. CD19, BCMA)
- **Tumor heterogeneity, T cell persistence** and ACT scale up challenging

**Solid tumors**

- CPI’s well established, combinations offer incremental benefit
- **Increasing activated, tumor-specific T cells in the tumor**, bypassing dysfunctional immune cells in TME is needed – with a scalable solution
- **Multi-antigen targeted therapies and combinations essential to address heterogeneity, drive persistence** and increase durable response

**Autoreactive T cells**

- Most treatments are non-specific, systemic (e.g., aTNF, aCD20) and globally suppress the immune system
- Emerging opportunity to **target autoreactive, disease-causing T cells directly** and leave healthy tissue alone

* Bispecific CD3 / Targeted T cell engagers
Summary: AIM™ (Artificial Immune Modulating) Platform and Products

Unique Pharmaceutical Approach to directing potent multi-antigen-specific T cell responses

Transforming Treatment Paradigms

• T cells are the most effective way to specifically target and kill cancer cells
• Therapeutics to **directly** drive durable T cell mediated responses
• Expanding accessible antigen combinations to address heterogeneity

• Validated MOA:
  • Early adoptive cell therapy clinical POC
  • Pre-clinical POC in oncology and AI

• Potential “IND Engine”: designed to generate new multi-antigen product INDs with increased speed

• Seeking to advance Injectable off-the-shelf IND in 2H2024 (Oncology)
NexImmune’s AIM™ platform products have breakthrough potential

Directing *antigen-specific T cell responses* across Oncology, Autoimmune and Infectious Diseases

- **AIM “aAPC” nanoparticles designed** to act as synthetic dendritic cells to deliver precise instructions directly to T cells through natural signaling mechanisms
- **Multi-antigen specific products designed to generate a T cell mediated response** without impacting healthy tissue or immune function (bypassing host DC)
  - Break tolerance and drive a durable response in Cancer - Activate and expand multiple antigen-specific T cell subtypes associated with anti-tumor activity, persistence and establishment of immunologic memory (Tscm, Tcm, Tem)
  - Establish tolerance in Autoimmune Disorders - Suppress or delete targeted antigen-specific autoreactive T cells
  - Direct T cells to kill virally infected cells in Infectious Diseases
- **“Off-the-shelf” Injectable products that are scalable**
One MOA - Two Therapeutic Modalities
Direct multi-antigen specific T cells to deliver potent, durable response

Establish ACT P1 POC, Advance INJ modality, a scalable, off-the-shelf solution

Validated MOA

1. ACT Early Clinical POC, INJ pre-clinical POC

2. Potent, multi-tumor-specific activated T cells that traffic to tumor and persist - Directly engages the broad TCR repertoire

3. Address Disease Heterogeneity
   Broad access to target combinations

Two Modalities
ACT and INJ

Established np and ACT platform clinical manufacturing process

Same proteins, np conjugation chemistry (change in core material)
Speed, Scale and Optionality: Reduced to Practice

Potential for more rapid multi-antigen product development within months - an “IND engine”

HPV product candidate (NEXI-003): From target validation and selection to filing new product IND in ~6 months*

Antigen-peptide “Unloaded” AIM nanoparticle

Validation and selection of disease specific antigen targets e.g. HPV example 2 months

Rapid multi-antigen new product development e.g. NEXI-003 example 6m*

- Manufactured in advance and stored in bulk aliquots for future use
- 3 clinical lots for ACT produced

- Partner world-class discovery and AI capabilities combined with NexImmune efforts
- Ability to screen and validate T cell responses to antigen targets which informs final selection (HPV example: validation screening of 50 peptides in 8 weeks)

- Rapid loading of multiple antigens (hours)
- Reduces time from target selection to new product IND to months
- Nanoparticle is “loaded” with single peptides and combined to make a custom disease specific mix

*Timing influenced by external CDMO; fill finish and release schedule
Pipeline: Developing the AIM technology in multiple therapeutic areas
Early collaboration with world-class centers, significant opportunity for disease specific partnering

### INJECTABLE MODALITY (AIM INJ)

<table>
<thead>
<tr>
<th>NAME</th>
<th>INDICATION</th>
<th>PRECLINICAL</th>
<th>PRE-IND</th>
<th>PHASE 1/2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEXI-100 series</td>
<td>Heme/Solid Tumor (e.g. viral related malignancies)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEXI-200 series</td>
<td>Autoimmune Diseases (e.g. T1D, vitiligo)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEXI-300 series</td>
<td>Infectious Diseases</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ADOPTIVE CELL THERAPY MODALITY (AIM ACT) *

<table>
<thead>
<tr>
<th>NAME</th>
<th>INDICATION</th>
<th>PRECLINICAL</th>
<th>PHASE 1/2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEXI-001</td>
<td>AML / MDS¹ (r/r post allo-HSCT)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEXI-002</td>
<td>Multiple Myeloma (r/r ≥3 prior lines of therapy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEXI-003</td>
<td>HPV-associated Malignancies (2L post CPI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEXI-004</td>
<td>EBV related diseases</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) who have relapsed disease after an allogeneic hematopoietic cell transplant (HCT) Clinical Trial: NCT04284228 [https://clinicaltrials.gov/ct2/show/record/NCT04284228](https://clinicaltrials.gov/ct2/show/record/NCT04284228)

Additional HLA’s in development

Key Collaborators

- New York University Perlmutter Cancer Center
- Yale University
- Johns Hopkins University
- JDRF
- NIH National Institutes of Health
- The Ohio State University
- City of Hope
- Dana-Farber Cancer Institute
- Memorial Sloan Kettering Cancer Center
- Columbia University

*AIM ACT programs have currently paused enrollment. NexImmune is actively seeking academic and industry partners and collaborators to continue development of the AIM ACT programs.
Oncology

The Power of Multi-Antigen-Specific T cells
AIM T cell Directing Approach: Combination of Differentiating Attributes

T cells are the most effective mechanism to identify and clear cancer cells and establish immunologic memory

1. Attack Multiple Tumor Targets Simultaneously
   - AIM T cell populations that can attack multiple tumor-specific antigen targets simultaneously to address heterogeneity
   - AIM T cells can attack a broad range of antigen targets - cell-surface proteins and survival proteins or neoantigens to increase response and limit escape
   - AIM T cell are active on tumors bearing non-targeted genetic and epigenetic changes

2. Increase Response and Persistence
   - AIM T cell subtypes (stem-cell-like memory T cells, central memory T cells) are associated with potent killing, self-renewal and long-term immunologic memory
   - Unlike fully differentiated effector T cells, which exhaust themselves in weeks or a few months (leading to tumor relapse), these subtypes persist for years or decades
   - Potent AIM activated specific T cells, traffic to the tumor site and persist

3. Natural TCR Safety Profile
   - AIM T cells maintain natural target recognition, engagement, activation and killing mechanisms
   - Can effectively distinguish healthy cells from tumor cells — low potential for on-target/off-tissue toxicity
   - Express a broad range of TCRs with both high and low affinity
NEXI-001 AML Therapeutic for r/r AML post allo-SCT and salvage therapy
POC for multi-AML antigen-specific T cell approach as cell therapy – 5 antigen peptide targets

Concentrated clinical activity of cell therapies around transplant window leaves high unmet need for heavily pretreated patients with no approved options

- Rapidly progressing, heterogeneous disease where most patients succumb within 1-year and the 2-year survival rate is < 10-15%.
- Infrequent remission rates of limited duration further decline with later lines of therapy, even when combining options

4 of 7 patients in last 2 cohorts achieved Best Status/Best Response of at least morphologic CR (up to 9+ mo)
Acceptable tolerability

Cohort 2: 200M / cycle (1-2 cycles)
Cohort 3: 600M / Cycle (1 cycle)

Planned Expansion/ P2
NEXI-001: Observed Dose Response
Percent of Antigen-specific CD8+ T cells increase and persist in blood and marrow with increasing dose, maintaining important phenotype

Antigen-specific T cells persisted and expanded in peripheral blood, trafficked to bone marrow and persist

<table>
<thead>
<tr>
<th>Total Antigen Specificity (% of CD8+ T cells)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohort 2 Patient 8 (200M)</td>
</tr>
<tr>
<td>Visit</td>
</tr>
<tr>
<td>Blood</td>
</tr>
<tr>
<td>M1</td>
</tr>
<tr>
<td>M3</td>
</tr>
<tr>
<td>Bone</td>
</tr>
<tr>
<td>M1</td>
</tr>
<tr>
<td>M3</td>
</tr>
</tbody>
</table>

Antigen-specific T cells maintain important memory subtypes over time

Patient 8
NEXI-001 Product

Month 3 memory of specific cells in bone marrow (WT1)
Optimize anti-tumor potency and durability in heterogeneous tumors

**Novel Combination** of Bispecific TCE with AIM TAA-specific “Fit” CD8+ T cells

1. **Increase potency and address escape**
   - Increase number of tumor targets (intracellular, surface)
   - Increase polyclonal multi-TAA specific T cells in tumor (direct trafficking to the tumor / T cell redirecting to tumor)
   - Combine MHC restricted and unrestricted killing

2. **Increase persistence / durability**
   TAA long lived memory cells, Tscm, Tcm in absence of bispecific

---

**Cancer Cell**

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients

---

(Dirco J. Friedrich et al, The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients, Cancer Cell, 2023)
Superior Potency when combining Bispecific TCE\(^1\) combination with AIM multi-targeted T cells across AML and Multiple Myeloma (MM) cell lines (low doses)

Combines HLA dependent / independent killing, expands target repertoire and increases specific, fit memory /effector T cells at the site of tumor - demonstrating superior potency compared to bulk CD8\(^+\) T cells + TCE (tumor cell lines); low doses of both agents

---

**AIM AML and MM specific CD8+ T cells are more “fit” defined by high proportions of Tscm, Tcm and Tem vs non-specific bulk CD8+ T cells from HD that were used to mimic TCE monotherapy**

Low E:T ratio + Low dose Bispecific; Antigen specific cells include Tscm, Tcm, Tem memory phenotypes associated with anti-tumor activity and persistence

---

\(^1\) TCE: aCD3 /Targeted T Cell Engager or BiTE’s
Multiple Myeloma: Superior Potency and Enhanced Persistence Combining BCMA TCE with AIM multi-antigen specific CTL\(^1\) (*Low Doses of both*)

Durable superior killing

<table>
<thead>
<tr>
<th>Photos/sec x 10^3</th>
<th>PBS</th>
<th>AIM ACT</th>
<th>AIM ACT + BiTE 0.5 µg/kg</th>
<th>AIM ACT + BiTE 2 µg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 x 10^-3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 x 10^-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 x 10^-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 x 10^0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 x 10^1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 x 10^2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 x 10^3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MM Specific T cells\(^1\)

Increased Survival

Data from Hackensack Lab; Day 0 tumor established, treatment started; Lower dose of T cells and low dose of BCMA bispecific agents

\(^1\)AIM ACT MM CTL's target CS1, CD138, WT1 NY-ESO; Mostly Tscm, Tcm, Tem T cell populations

NexImmune Corporate Presentation

October 2023
Melanoma: Superior anti-tumor effect and increased survival
NEXI MART-1-specific T cell treated mice

Superior Reduction in Mean Tumor Volumes Over Time
Human Melanoma Model (PDX)

Superior Survival - Kaplan-Meier Survival Plot of
Time to Tumor Volume ≥ 2000 mm³
Human Melanoma Model

Persistence of MART-1 CD3+CD8+ T Cells (TIL) Over Course of Study (D97 last day measured)

In the treatment group, 8/15 mice (53%) survived to end-of-study (D97), with ORR = 6CR, 1PR, 1SD. All vehicle-treated mice expired on study.

1 MART-1 specific T cells primarily Tscm, Tcm and Tem phenotypes associated with anti-tumor killing and persistence
Melanoma: AIM expanded CD8+ T cells possess superior anti-tumor activity compared to those expanded by mature peptide-pulsed DCs (Melanoma patients n=3, PBMC)

Study Conclusions

- Demonstrated consistent expansion of MART-1 from HD and Melanoma patient (PBMC)
- Significantly greater killing with AIM expanded MART-1 T cells vs DC expanded T cells
- AIM expanded MART-1 T cells were equally polyclonal (TCR diversity) with greater affinity vs DC expanded T cells

Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells

Current Project:
Evaluate ability of AIM nanoparticles to expand neoantigen-specific T cells in previously treated melanoma patients
The AIM INJ nanoparticle directly expands multi-antigen specific T-cells designed to address heterogeneity and increase durable efficacy

Early success with modalities focused on increasing antigen specific CD8+ T killing

Cancer Therapeutic Vaccines (rely on host DC to activate T cells)

Bi- (Tri-) specific TCE Antibodies

NexImmune

- Direct activation and expansion of antigen-specific T cells, bypassing dendritic cells – which frequently become dysfunctional in cancer
- Broad accessible targets (surface, intracellular)
- Simultaneous activation of “fit” multi-tumor specific CD8+ T cells (heterogeneity) for increased efficacy and durability
- Scalable, Off-the-shelf -simplify logistics, access
“Antigen-peptide Loaded” AIM INJ nanoparticles traffic to lymph nodes, spleen and tumor compared to “naked” nanoparticles

Studies done in an oncology model illustrate how AIM nanoparticles (e.g., loaded with target antigen) that are administered systemically travel naturally to critical immune sites (96 hrs)

**“Naked” nanoparticle** without proteins or peptide targets in tumor-bearing mice

**AIM nanoparticle** with peptide-loaded proteins in tumor-bearing mice

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Mean (%ID/g/Tissue)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>0.00</td>
</tr>
<tr>
<td>Large Intestine</td>
<td>2.00</td>
</tr>
<tr>
<td>Pancreas</td>
<td>4.00</td>
</tr>
<tr>
<td>Muscle</td>
<td>6.00</td>
</tr>
<tr>
<td>Stomach</td>
<td>34.24</td>
</tr>
<tr>
<td>Salivary Gland</td>
<td>20.00</td>
</tr>
<tr>
<td>Bladder</td>
<td>12.00</td>
</tr>
<tr>
<td>Lung</td>
<td>8.00</td>
</tr>
<tr>
<td>Heart</td>
<td>4.00</td>
</tr>
<tr>
<td>Small Intestine</td>
<td>2.00</td>
</tr>
<tr>
<td>Muscle</td>
<td>1.00</td>
</tr>
<tr>
<td>Fat</td>
<td>0.00</td>
</tr>
<tr>
<td>Liver</td>
<td>0.00</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.00</td>
</tr>
<tr>
<td>Tumor</td>
<td>0.00</td>
</tr>
</tbody>
</table>

34.24
AIM INJ NPs significantly increased antigen-specific T cells in spleen and tumor with greater killing when compared to peptide in CFA.

B16-OVA (implanted OT-1 T cells); OVA loaded NP compared to OVA peptide in CFA

In vitro killing assay with splenocytes harvested on day 22 (n=2)
Reproducible: 7-16-fold increase of antigen-specific activated T cells using “Peptide loaded” INJ nanoparticles (3 models, multiple targets)

The activated antigen-specific T cells are polyfunctional, maintaining effector and memory functions with no exhausted phenotypes

7-fold increase in OVA specific CD8+ T cells in LN (non-disease, MOA study, day 7)

7-fold increase in multi-antigen specific CD8+ T cells in tumors (melanoma, B16F10)

16-fold increase in gp100 specific CD8+ in tumors (melanoma B16F10, D13)

...which maintain effector and memory functions

...which are polyfunctional with 63% of CD3+/CD8+ T cells having 3+ effector functions

..which maintain effector and memory functions with continued exposure to tumor

October 2023
Significant AIM np single ascending dose dependent *in vivo* killing of antigen pulsed target cells in Spleen and LN (OVA-loaded AIM INJ activated T cells)

Mice were injected with OT-1 cells (D0); single, ascending sc dose of np (D1); CSFE labeled, peptide pulsed targets (splenocytes) were administered i.v. (D9); and killing of target cells was measured by flow (D10)

Dose Dependent Specific Killing Spleen (CFSE$^{hi}$)

Dose Dependent Specific Killing Lymph Node (LN) (CFSE$^{hi}$)

N=3 mice/group; CFSE fluorescence cell mediated killing assay
NEXI-101 AIM INJ Product: HPV+ HNSCC Lead indication
Multi-antigen targeted approach has broad potential in HPV+ Cancers

- HPV+ cancers represent ~5% of all cancers globally, ~300,000 new cases / year globally, and >45,000 new cases per year in the US (ref)

- HPV vaccines are not approved to treat related malignancies and with marginal vaccination rates, many remain vulnerable

- Treatments include chemo and checkpoint inhibitors (CPI) yet responses remain low

- Estimated 79% of cervical, vulvar, penile, vaginal, anal, and oropharyngeal cancers attributed to HPV, predominantly high-risk HPV 16 and 18 strains.

- Oncoproteins E6 and E7 are important for cancer survival; and DC impairment in directing T cells to tumor targets has been observed in cervical and HN cancers

NEXI-101 HPV+ Solid Tumor Vision

Direct simultaneous T cell responses against both high-risk strains and cancer survival proteins

Targets: HPV-16 (E6, E7) and HPV-18 (E6, E7), survivin

1. ESTABLISH monotherapy (Head and Neck cancer)

Dose escalation (RP2D) and expansion phase

2. COMBINE with current CPI SOC (RP2D)

3. EXPAND into basket trial of HPV+ cancers and additional HLA’s when available

RP2D, Recommended Phase 2 Dose; PD, pharmacodynamics; CPI, Checkpoint Inhibitor(s) approved for the indication
IO/IO treatment paradigm shift:
Combining multi-antigen T cells with current and emerging approaches to limit escape and increase response

*Block T cell inhibition* to increase T cell killing

**Checkpoint Inhibitors**
e.g. (PD(L)-1, TIGIT)

*Redirect T cells to the tumor to increase T cell killing*

T cell engaging Bi-specifics

*Increase multi-TAA T cell killing* to limit escape and increase persistence

*Increase CAR-T cell killing*
CD19, BMCA, other
Beyond Oncology

Autoimmune Disorders and Virally Driven Diseases
Autoimmune Disorders: AIM nanoparticles designed to target and suppress, or delete disease causing antigen specific T cells

Antigen-targeting therapies are emerging focus in autoimmune disorders; the AIM™ platform has the potential to address multiple areas of unmet need.
Leading experts guide T1D program:

Recent publications in Type 1 diabetes suggest targeting stem like CD8+ autoreactive cells could emerge as a novel, powerful intervention.

- Collaboration with Dr. Kevan Herold and Yale for murine model research
- Dr. Gerry Nepom (Director, Immune Tolerance Network) as Chair of NexImmune’s Autoimmune SAB
- Based on early findings, received significant grant from Juvenile Diabetes Research Foundation (JDRF) to support and accelerate work
- Data continues to be encouraging and supports our technology as potentially breakthrough and disruptive therapeutic in T1D

NexImmune: Autoimmune SAB Members

Kevan Herold, MD, C.N.H. Long Professor of Immunology, Yale University

Gerry Nepom, M.D., PhD
Director, ITN; Founder of Benaroya Research Institute
AIM INJ significantly reduces and inhibits T1D disease causing T-cells in lymph node and pancreas delaying onset of T1D (Antigen presentation, signal 1 only)

T1D specific T cells in the pancreas of 13-week-old NOD mice are significantly less activated than in control mice; Signal 1 (Antigen presentation)

~20% Reduction of T1D disease renewing cells
Tscm, lymph node

~25% Reduction of T1D T cells
Tem, Pancreas

~30% Reduction of T1D T cell activation
Tem, Pancreas

T1D specific T cells in pre-diabetic NOD mice

Pancreatic Lymph Node (LN)
1-6% T1D NRPV7+ T cells in LN

Pancreas
15-30% T1D NRPV7+ T cells in pancreas
After 7 weeks, S1 only

S1+S2 POM: HLA/PD-L1-Ig inhibits antigen-specific CD8+ T cell function (cytotoxic activity) – Yale initiated in vivo study

Signal 2 options in development to enable antigen-specific suppression (PDL1-Ig) or elimination (anti-Fas) in autoimmune diseases

PDL1-Ig-NP inhibits antigen-specific killing of peptide loaded target cells

Mart-1 cells were incubated for 90 minutes with 50 μg/ml nanoparticles. After washing cells were incubated with peptide loaded targets for 4 hours and antigen specific killing was assessed by caspase 3/7 assay.
S1+S2 POM: Combined HLA / a-FAS nanoparticles demonstrate initial antigen-specific CD8+ apoptosis within 4 hours leaving non-target cells alone

HLA / anti-Fas np eliminates 50% of MART-1 antigen-specific CD8+ T cells

- Dose dependent effect observed
- Time course evaluation planned
Novel functional validation: 3rd dimension can enhance target discovery and screening
Well understood that immune cells can become dysfunctional in the face of cancer and certain other diseases

Multiple approaches to target discovery
• Tissue, tumor, TCR
• Genomic, proteomic, immunopeptidomes and transcriptomes

Screening and algorithms primarily focus on:
• High affinity TCR’s (assumes target on tumor)
• Prevalence of target (on tumor cells)
• Affinity enhanced TCR’s
• Absence /low detection on healthy tissue

Affinity is an important factor in selecting targets or TCR’s, however, high affinity does not always correlate with best response
HPV Example: Rapid T-cell based screening and functional validation of targets
Screened 50 targets for HPV+ cancer(s) product mix selection

Selection of targets and Disease-specific Product Mix

Rapid Screening for Antigen-Specific T cell Response

Antigen specific responses / 50 peptide targets

76% of Specific T cells Expressed >3 Effector Functions

Potent Antigen-specific Killing (HLA-A2) CaSki

Selection of targets and Disease-specific Product Mix

*Cells stimulated non-specific (ICS), A2 - Killing of tumor target / A2- not shown
No single factor predicts function, no single peptide provides broadest response

**Initial Peptide Screen**
- KOL’s and literature
- Reports of efficacy and safety
- Peptide scouting and discovery
- *In silico* investigation and triage

**Prediction Evaluation**

**Multiplex cell based Functional Evaluation**
Targeting a broad range of TCR’s:
- Specificity
- Range of affinities
- Functional (e.g. killing) capacity

---

**Graph:**
- X-axis: Predicted IC50 (thousands nM)
- Y-axis: % Specificity
- Data points:
  - High Affinity
  - Predicted IC50
  - Low Affinity
  - Affinity-specificity
  - 40-60% killing combined
  - 60-80% killing combined
  - 40-60% killing individual
  - 60-80% killing individual
EBV/MS Example: AIM based Functional Validation reveals functional defect in MS patients to EBV specific peptide(s)

Antigen-specific T-cell approach represent a disruptive clinical strategy over current MS treatments

Collaboration with Steve Jacobson’s Lab

- Expanded EBV specific T cells similar between HD and MS PBMC
- However, specific T cell defects against known EBV targets were identified in treated patients

Collaboration with David Hafler’s Lab

- Evaluate functional status of T cell responses to specific EBV targets in MS patients at initial diagnosis (blood and tissue)
- Inform strategies for multi-antigen therapies to improve outcomes

EBV antigen specificity from healthy donors & MS patients

![Graph showing EBV antigen specificity from healthy donors and MS patients. The x-axis represents different EBV antigens, and the y-axis represents specificity (%). The graph includes a comparison between healthy donors and MS patients, with several antigens such as EBV LMP1 YLL, EBV LMP1 YLQ, EBV LMP2 FLY, EBV BMLF1, EBV EBNA3, and EBV BRLF1. The data shows some specificity differences between healthy donors and MS patients, indicated by ns (not significant).]
Advance Transformative Paradigms with multi-antigen specific therapeutics
Collaborative target selection, product development and combinations

- **Establish** Functional validation (targets)
- **Establish** ACT POC and IND engine (Oncology)
- **Expand** HLA Eligibility – 2024
- **Advance** novel IO combinations
- **Extend into** Class II diseases - 2024
- **Explore** novel AIM modalities and payload delivery

- Novel multi-antigen specific products with potential to direct T cell function
- Synergistic IO/IO combinations
- Collaborative approach to advance new indications and combinations
- Functional validation dimension to enhance target prediction
- Platform-based IND engine
- Initial manufacturing platforms established
- Broad IP

Establish and Expand INJ
Oncology IND 2024e
Collaborations in Oncology, AI, ID
Potential to Transform Treatment Paradigms: Designed to deliver durable antigen-specific T cell responses

• Validated Oncology MOA: Early Clinical POC; consistent pre-clinical data across indications, ACT and INJ
  • Address heterogeneity to increase response and persistence
  • “Fit” tumor specific T cells ideal for synergistic Immunotherapy combinations

• Validated Autoimmune MOA: Eliminate or inhibit autoreactive, diseases-causing T cells (T1D*, pre-clinical)

• Reproducible data across multiple collaborations and KOL’s – demonstrate broad potential

• Potential “IND Engine” designed to rapidly generate new multi-antigen product INDs

• Advancing T-cell based functional validation of targets designed to enhance target discovery and improve success

• Unlocking significant expansion opportunities with INJ and next generation approaches (e.g. Class II, bifunctional signaling)

* AI pre-clinical data generated via external collaborators
Thank You

NASDAQ: NEXI